Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$5.41 USD
-0.03 (-0.55%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
FATE 5.41 -0.03(-0.55%)
Will FATE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FATE
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Other News for FATE
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics CFO Glenn Goddard to step down, Edward Dulac to succeed
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday